Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Aesica Extends Aseptic Facilities at Nottingham Site

Published: Tuesday, October 08, 2013
Last Updated: Tuesday, October 08, 2013
Bookmark and Share
Batches can be delivered worldwide for clinical trials and within the EU for small-scale commercial production.

Aesica has extended its aseptic capabilities at its Nottingham site with the acquisition of new pre-filled syringes manufacturing equipment capable of processing 5000 units/batch.

This latest addition, currently undergoing its validation via process simulation trials, provides Aesica with the ability to service clients across the EU and US markets - opening up the fastest growing area within the pharmaceutical development sector.

Such is the demand within this market that several clients have already started approaching the CDMO to begin discussion for production into clinical trials.

The product is seeing huge growth both in the US and Europe, particularly for trials involving proteins and vaccines, as it removes the risk of dosing errors, contamination and needle injuries.

The company has already invested in the specialist technology with the total investment predicted to rise to be over £500,000 on completion of the validation process - due by January 2014.

The prefilled syringes market is currently worth over £1 billion and growing rapidly, however the Company’s new equipment also opens up sales opportunities for Aesica to produce more innovative products like pen and cartridge syringes, and nasal devices.

Over the next three years, Aesica is targeting production of 900,000 units and is already in advanced discussions with one company for the scale-up of a clinical trial product for which a joint validation is imminent.

Ian Lafferty, Site Director Nottingham, added: “Over the last few years, Aesica has really accelerated its credibility in the aseptic market and pre-filled syringes are a natural evolution towards providing a complete product portfolio for our clients, and a reflection of the direction the wider market is heading. Demand is increasing for these products and very few other CDMOs are currently able to supply this in such quantities for clinical trials. Biotechnology companies are already starting to make contact with us and I would envisage a steady uptake across the US and in particular Europe where we are likely to see huge growth rates.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aesica Honoured with Prestigious Award
The CDMO secures the accolade for a sixth time through its talented personnel.
Monday, April 11, 2016
Aesica Adds Development Capability at Queenborough
Product life cycle services expanded including for high potent and controlled drugs.
Tuesday, April 05, 2016
The New Aesica Development Centre
Strategic relocation of development and clinical manufacturing services from Nottingham to Queenborough is now complete.
Wednesday, January 20, 2016
Aesica on Recruitment Drive at Queenborough Site
Aesica Pharmaceuticals has announced that it is actively recruiting for more skilled personnel at Queenborough ahead of the launch of its new development centre at the site.
Thursday, January 14, 2016
Bespak and Aesica Unveil New Single Source Supply Chain Solution
Supply chain solution for drug delivery device and pharmaceutical manufacturing services.
Friday, November 13, 2015
Aesica Introduces New Service Model with One CDMO
The company’s solution radically simplifies supply chain management – optimizing efficiency, improving performance and bringing products to market faster.
Wednesday, October 21, 2015
Aesica Launches New Brand Identity
Official launch to the market is planned for 13th October.
Tuesday, October 13, 2015
Aesica Secures Continuing FDA Approval of its Bulk Manufacture and Packaging Sites
FDA inspection results means Aesica will continue to grow its manufacturing and packaging services for pharmaceutical products for the US market.
Tuesday, February 03, 2015
Aesica Appoints VP, Business Development and Business Development Director
Appointment of Detlef Behrens and Sven Wrabletz for finished dose to drive service in Europe and achieve further growth.
Friday, October 31, 2014
Aesica Appoints New Product Release Manager
Company announces appointment of Adam Burgess.
Wednesday, August 20, 2014
Aesica Zwickau Marks 20th Anniversary
Continued growth and expansion of Company’s encapsulation services business.
Saturday, July 19, 2014
Aesica Recruits New Business Development Manager
Appointment of Nadine K. Reuter to aid sales drive across German, Austrian and Swiss Markets.
Thursday, July 03, 2014
Aesica Collaborates with QAD to Meet CFDA’s Shortened Serialization Deadline
The new system was implemented within three months.
Saturday, June 28, 2014
Aesica Successfully Introduces Serialization Services at Italian Site
Initiates commercial production of two product lines for the Chinese market.
Thursday, April 17, 2014
Aesica Led Consortium Wins Technology Strategy Board Grant
Funding secured for the consortium’s project to investigate an industrial biotechnology process to enable improved manufacture of an API.
Tuesday, April 08, 2014
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
MRSA Uses Decoys to Evade a Last-Resort Antibiotic
Researchers at Imperial College London have discovered that MRSA releases decoy molecules that allow them to escape being killed by the antibiotic.
Fighting Cancer with Immune Response
New treatment elicits two-pronged immune response that destroys tumors in mice.
Nanomedicine for Breast Cancer Treatment
Using nanoparticles measuring only billionths of a meter in size, doctors are able to deliver drug molecules directly to the affected tissue.
Preventing "Friendly Fire" in the Pancreas
Researchers inhibit process that leads to the body attacking its own insulin-producing cells.
RNA-Binding Proteins Role in ALS Revealed
Researchers describe how damage to RNA-binding protein contributes to ALS, isolating a possible therapeutic target.
Zika Virus Infection Alters Human and Viral RNA
Researchers have discovered that Zika infections results in human and viral genetic modification.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos